Core Viewpoint - Xinguang Pharmaceutical (300519) has announced that its new drug "YHTKL" has completed the basic research of prescriptions and is now entering the stage of process and quality standard research [1] Group 1 - The company has responded to investor inquiries on its interactive platform regarding the progress of its new drug [1] - The new drug "YHTKL" is currently in the process of developing its quality standards [1]